Lupin receives FDA approval for generic Triamcinolone Acetonide Ointment
New Delhi: Pharma major Lupin announced that it has received approval for its Triamcinolone Acetonide Ointment USP, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Mylan Pharmaceuticals, Inc.’s (Mylan) Triamcinolone Acetonide Ointment, 0.1%.
Lupin’s Triamcinolone Acetonide Ointment USP, 0.1% is the generic version of Mylan’s Triamcinolone Acetonide Ointment, 0.1%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Triamcinolone Acetonide Ointment USP, 0.1% had annual sales of approximately USD 25.7 million in the US (IQVIA MAT June 2018).
Read Also: Lupin antimyotonic agent receives positive opinion from EMA
Lupin’s Triamcinolone Acetonide Ointment USP, 0.1% is the generic version of Mylan’s Triamcinolone Acetonide Ointment, 0.1%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Triamcinolone Acetonide Ointment USP, 0.1% had annual sales of approximately USD 25.7 million in the US (IQVIA MAT June 2018).
Read Also: Lupin antimyotonic agent receives positive opinion from EMA
FDALupinMylanMylan PharmaceuticalsTriamcinolone Acetonide OintmentUnited States Food and Drug AdministrationUSFDA
Source : SelfMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd